THE INFLUENCE OF AWARENESS OF PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS ABOUT THE MAGNITUDE OF THE FRAX 10-YEAR ABSOLUTE RISK OF FRACTURE ON THE DECISION TO START AND THE ADHERENCE TO ANTIOSTEOPOROTIC TREATMENT (INTERIM RESULTS OF «CRYSTAL» STUDY)

To assess the influence of informing patients with postmenopausal osteoporosis about the their probability of 10-year absolute fracture risk calculated by FRAX tool on the patient ’s decision to start treatment and their adherence to therapy during 3 years of follow-up. Materials and Methods. Multicenter open randomized trial included 417 women (mean age 65.9 years). Patients of the 1 group (n=191) were informed about the value of their absolute risk of fracture by FRAX. Patients of the 2 group (the control; n=196) got usual advice and recommendations without calculating FRAX. All patients were recommended to take alendronate in a standard dose (70 mg a week) and calcium/vitamin D supplements. Results. During the first three months after initial visit 96.4% of patients started their treatment. The adherence to treatment at sixth month was 7% higher in the group 1; the compliance in the group 1 was 8% higher, than in the control group. 6.4% of patients developed adverse drug reactions, which led to cancellation of therapy in only 2.9% of patients.

FRAX, postmenopausal osteoporosis, absolute risk, FRAX, 10-year fracture risk

1. Лесняк О.М. Аудит состояния проблемы остеопороза в Российской Федерации. Профилактическая медицина. 2011, т. 14, № 2, 7-10.

2. Yuksel N., Majumdar S.R., Biggs C., Tsuyuki R.T., et al. Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int. 2010 Mar; 21(3): 391-8.

3. Majumdar S.R., Beaupre L.A., Harley C.H., et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med. 2007 Oct 22; 167(19): 2110-5.

4. Majumdar S.R., Johnson J.A., McAlister F.A., et al. Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ. 2008 February 26; 178(5): 569-575.

5. Majumdar S.R., Johnson J.A., Bellerose D., et al. Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int. 2011 Jan; 22(1): 223-30.

6. Кузнецова Е.В., Евстигнеева Л.П., Лаврентьев А.С., и др. Выявляемость и лечение остеопороза у пациентов старших возрастных групп с переломом дистального отдела предплечья. Уральский медицинский журнал. 2010; 7: 91-96.

7. Новикова В.А., Пенжоян Г.А., Федорович О.К., и др. Современный взгляд на риски остеопороза и возможности его профилактики и лечения у женщин в постменопаузе. Акушерство и гинекология. 2013; 1: 27-32.

8. Black D.M., Thompson D.E., Bauer D.C. and FIT research group. Fracture risk reduction in women with osteoporosis: the Fracture Intervention Trial. J. clin. Endocr. 2000; 85: 4118-4124.

9. Black D.M., Schwartz A.V., Ensrud K.E., et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006 Dec 27; 296(24): 2927-2938.

10. Лесняк О.М. Новая парадигма в диагностике и лечении остеопороза: прогнозирование 10-летнего абсолютного риска перелома (калькулятор FRAX). Остеопороз и остеопатии. 2012; 1: 23-28.